Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Sep;40(9):1977–1982. doi: 10.1128/aac.40.9.1977

Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae.

B Barry 1, M Muffat-Joly 1, J Bauchet 1, F Faurisson 1, P Gehanno 1, J J Pocidalo 1, C Carbon 1
PMCID: PMC163458  PMID: 8878566

Abstract

We used a gerbil model of otitis media to assess the efficacy of single-dose ceftriaxone against three Streptococcus pneumoniae strains highly resistant to penicillin (MICs, 4 to 8 micrograms/ml) and with various susceptibilities to ceftriaxone (MICs, 0.5, 4, and 8 micrograms/ml). Middle ear infection was induced by bilateral transbullar challenge with 10(7) bacteria per ear. Antibiotic treatment was administered subcutaneously at 2 h postinfection. Infection status was checked 2 days later by counting the bacteria in middle ear and cerebrospinal fluid samples. With the cefriaxone-susceptible strain (MIC, 0.5 microgram/ml), we tested doses of 5 to 100 mg/kg of body weight. With a dose of 50 mg/kg, treatment outcome was equivalent to that with amoxicillin, which was used as a reference (25 mg/kg, two injections); no bacteria were recovered from 82% of the middle ear samples, and the rate of cerebrospinal fluid culture positivity was significantly reduced to 6%, relative to 59% for the untreated controls. Similar efficacy was obtained with a dose of 100 mg/kg against the two ceftriaxone-resistant strains. Pharmacokinetic study indicates that the values of the parameters in plasma after the administration of a dose of 100 mg/kg (peak level of total drug, 268 +/- 33 micrograms/ml; elimination half-life, 0.8 h; area under concentration-time curve, 488 micrograms.h.ml-1) were still suboptimal compared with the values of the parameters measured in pediatric patients after intravenous or intramuscular administration of a dose of 50 mg/kg. Our results indicate the efficacy of ceftriaxone against experimental cephalosporin-resistant pneumococcal otitis and provide a basis for the clinical use of single-dose ceftriaxone against pneumococcal otitis media.

Full Text

The Full Text of this article is available as a PDF (234.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baquero F., Loza E. Antibiotic resistance of microorganisms involved in ear, nose and throat infections. Pediatr Infect Dis J. 1994 Jan;13(1 Suppl 1):S9–S22. doi: 10.1097/00006454-199401001-00003. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Brown S. D., Novick W. J. In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates. Antimicrob Agents Chemother. 1995 Oct;39(10):2193–2196. doi: 10.1128/aac.39.10.2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barry B., Muffat-Joly M., Gehanno P., Pocidalo J. J. Effect of increased dosages of amoxicillin in treatment of experimental middle ear otitis due to penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 1993 Aug;37(8):1599–1603. doi: 10.1128/aac.37.8.1599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Catalán M. J., Fernández J. M., Vazquez A., Varela de Seijas E., Suárez A., Bernaldo de Quirós J. C. Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clin Infect Dis. 1994 May;18(5):766–769. doi: 10.1093/clinids/18.5.766. [DOI] [PubMed] [Google Scholar]
  5. Cleveland K. O., Threlkeld M. G., Tenover F. C., Leggiadro R. J. Drug-resistant pneumococcal meningitis in an American adult. Clin Infect Dis. 1995 Jun;20(6):1572–1573. doi: 10.1093/clinids/20.6.1572-a. [DOI] [PubMed] [Google Scholar]
  6. Del Rio M., McCracken G. H., Jr, Nelson J. D., Chrane D., Shelton S. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother. 1982 Oct;22(4):622–627. doi: 10.1128/aac.22.4.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Figueiredo A. M., Connor J. D., Severin A., Vaz Pato M. V., Tomasz A. A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone. Antimicrob Agents Chemother. 1992 Apr;36(4):886–889. doi: 10.1128/aac.36.4.886. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fraschini F., Braga P. C., Scarpazza G., Scaglione F., Pignataro O., Sambataro G., Mariani C., Roviaro G. C., Varoli F., Esposti G. Human pharmacokinetics and distribution in various tissues of ceftriaxone. Chemotherapy. 1986;32(3):192–199. doi: 10.1159/000238415. [DOI] [PubMed] [Google Scholar]
  9. Friedland I. R., Shelton S., Paris M., Rinderknecht S., Ehrett S., Krisher K., McCracken G. H., Jr Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J. 1993 Mar;12(3):196–200. doi: 10.1097/00006454-199303000-00004. [DOI] [PubMed] [Google Scholar]
  10. Fulghum R. S., Brinn J. E., Smith A. M., Daniel H. J., 3rd, Loesche P. J. Experimental otitis media in gerbils and chinchillas with Streptococcus pneumoniae, Haemophilus influenzae, and other aerobic and anaerobic bacteria. Infect Immun. 1982 May;36(2):802–810. doi: 10.1128/iai.36.2.802-810.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gehanno P., Lenoir G., Berche P. In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother. 1995 Jan;39(1):271–272. doi: 10.1128/aac.39.1.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Giebink G. S., Schiffman G., Petty K., Quie P. G. Modification of otitis media following vaccination with the capsular polysaccharide of Streptococcus pneumoniae in chinchillas. J Infect Dis. 1978 Oct;138(4):480–487. doi: 10.1093/infdis/138.4.480. [DOI] [PubMed] [Google Scholar]
  13. Green S. M., Rothrock S. G. Single-dose intramuscular ceftriaxone for acute otitis media in children. Pediatrics. 1993 Jan;91(1):23–30. [PubMed] [Google Scholar]
  14. Iliadis A., Brown A. C., Huggins M. L. APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics. Comput Methods Programs Biomed. 1992 Aug;38(4):227–239. doi: 10.1016/0169-2607(92)90103-e. [DOI] [PubMed] [Google Scholar]
  15. John C. C. Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clin Infect Dis. 1994 Feb;18(2):188–193. doi: 10.1093/clinids/18.2.188. [DOI] [PubMed] [Google Scholar]
  16. Martin E., Koup J. R., Paravicini U., Stoeckel K. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. J Pediatr. 1984 Sep;105(3):475–481. doi: 10.1016/s0022-3476(84)80032-3. [DOI] [PubMed] [Google Scholar]
  17. Moine P., Vallée E., Azoulay-Dupuis E., Bourget P., Bédos J. P., Bauchet J., Pocidalo J. J. In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother. 1994 Sep;38(9):1953–1958. doi: 10.1128/aac.38.9.1953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Routledge P. A. Pharmacokinetics in children. J Antimicrob Chemother. 1994 Aug;34 (Suppl A):19–24. doi: 10.1093/jac/34.suppl_a.19. [DOI] [PubMed] [Google Scholar]
  19. Ruuskanen O., Heikkinen T. Otitis media: etiology and diagnosis. Pediatr Infect Dis J. 1994 Jan;13(1 Suppl 1):S23–S54. [PubMed] [Google Scholar]
  20. Schaad U. B., Stoeckel K. Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother. 1982 Feb;21(2):248–253. doi: 10.1128/aac.21.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Scully B. E., Fu K. P., Neu H. C. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. Am J Med. 1984 Oct 19;77(4C):112–116. [PubMed] [Google Scholar]
  22. Sloas M. M., Barrett F. F., Chesney P. J., English B. K., Hill B. C., Tenover F. C., Leggiadro R. J. Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J. 1992 Aug;11(8):662–666. [PubMed] [Google Scholar]
  23. Steele R. W., Eyre L. B., Bradsher R. W., Weinfeld R. E., Patel I. H., Spicehandler J. Pharmacokinetics of ceftriaxone in pediatric patients with meningitis. Antimicrob Agents Chemother. 1983 Feb;23(2):191–194. doi: 10.1128/aac.23.2.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Stoeckel K., McNamara P. J., Brandt R., Plozza-Nottebrock H., Ziegler W. H. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther. 1981 May;29(5):650–657. doi: 10.1038/clpt.1981.90. [DOI] [PubMed] [Google Scholar]
  25. Varsano I., Frydman M., Amir J., Alpert G. Single intramuscular dose of ceftriaxone as compared to 7-day amoxicillin therapy for acute otitis media in children. A double-blind clinical trial. Chemotherapy. 1988;34 (Suppl 1):39–46. doi: 10.1159/000238646. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES